Targeted therapy in renal cell carcinoma

Bibliography

• SOCIETY AC: Cancer facts and figures, American Cancer Society (2003)4.
   Google Scholar
• DUTCHER JP: Interleukin-2 based therapy for kidney cancer. Cancer Treat. Eec. (2003) 116:155–172.
   PubMedGoogle Scholar
• COLLICHIO FAMDP, KISHAN MD: Interferon [a]-2b and megestrol acetate in the treatment of advanced renal cell carcinoma: a Phase II study. Am.. Oncol (1998) 21(2):209–211.
   PubMed Web of Science ®Google Scholar
• PYRHONEN S, SALMINEN E, RUUTU M et al: Prospective randomized trial of interferon a2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. (1999) 17:2859–2867.
   PubMed Web of Science ®Google Scholar
• WAGNER J, LINEHAN WM: Molecular genetics of renal cell carcinoma.]. Urol. Oncol (1996) 14(4):244–249.
   Google Scholar
• ••An excellent review.
   Google Scholar
• GNARRA DD Jr, WENG Y, JS et al: Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal cell carcinoma. Biochim. Biophys. Acta (1996) 1242(3):201–210.
   PubMed Web of Science ®Google Scholar
• KAELIN W: The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. (2004) 10(18 Part 2):62905–62955.
   Google Scholar
• ••Excellent review of the genetics of kidneycancer.
   Google Scholar
• DATTA K, SUNDBERG C, KARUMANCHI SA, D: The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and. Cancer Res. (2001) 61 (5): 1768–1775.
   PubMed Web of Science ®Google Scholar
• BARNES C, KUMAR R: Biology of the epidermal growth factor receptor family. Cancer Treat. Res. (2004) 119:1–13.
   PubMedGoogle Scholar
• ••Important paper on the EGFR family.
   Google Scholar
• DAWSON N, GUO C, ZAK R et al.: A Phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma. Proc. Am. Soc. Clin. Oncol (2003) 22:404 (Abstract 1623).
   Google Scholar
• JERMANN MJM, PLESS M, M et al.: An open-label Phase II trial to evaluate the efficacy and safety of gefitinib in patients with locally advanced, relapsed or metastatic renal cell cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:418 (Abstract 1681).
   Google Scholar
• ROWINSKY SG, GOLLOB JA, THOMPSON JA et al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. (2004) 22 (15) :3003–3015.
   Google Scholar
• MOTZER RJ, TODD M, HWU WJ et al.: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.. New Drugs (2003) 21(1):99–101.
   Google Scholar
• FERRARA N, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669–676.
   PubMed Web of Science ®Google Scholar
• GERBER KJ, SHERMAN D, DA, FERRARA N: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. (2000) 60(22):6253–6258.
   PubMed Web of Science ®Google Scholar
• KIM KJ, WINER J, ARMANINI M, GILLETT N, PHILLIPS HS, N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362(6423):841–844.
   PubMed Web of Science ®Google Scholar
• PREWETT MHJ, LI Y, SANTIAGO A et al.: Antivascular endothelial growth factor receptor (fetal liver kinase I) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. (1999) 59(20):5209–5218.
   PubMed Web of Science ®Google Scholar
• YANG JCHL, SHERRY RM, HWU P et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl. I Med. (2003) 349(5):427–434.
   PubMed Web of Science ®Google Scholar
• GEORGE DMD, OH WK, REITSMA D et al: Phase I study of PTK-787/ ZK-222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc. Am. Soc. OM. Oncol (2003) 22:385 (Abstract 1548).
   Google Scholar
• MORGAN BTA, DREVS J, HENNIG J et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK-787/ ZK-222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol (2003) 21(21):3955–3964.
   PubMed Web of Science ®Google Scholar
• DE BAZELAIRE CDA, ROFSKY N, WANG Y et al: MRI-assessed changes in tumor blood flow following treatment with PTK/ZK correlate with subsequent tumor shrinkage or growth in patients with metastatic renal cell carcinoma. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics,, USA (2003).
   Google Scholar
• DREVS M-DR, WITTIG C, FUXIUS S et al: PTK-787/ZK-222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. (2002) 62(14):4015–4022.
   PubMed Web of Science ®Google Scholar
• VUKY J FM, ISACSON C, CRUZ J et al: Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol (2003) 22:416.
   PubMedGoogle Scholar
• HAINSWORTH SJ, SPIGEL DR, SCHWERT RC, CARRELL DL, HUBBARD F, GRECO FA: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(14S):4502.
   Google Scholar
• SPIGEL DR, SOSMAN JA, RAEFSKY EL et al.: Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a Phase II multicenter trial. 2005 ASCO Annual Meeting, Orlando, USA (2005).
   Google Scholar
• HAINSWORTH JD, SPIGEL DR, PATTON JF et al.: Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): a Minnie Pearl Cancer Research Network Phase I/II trial. 2005 ASCO Annual Meeting, Orlando, USA (2005).
   Google Scholar
• SCHWARTZ L, WANG MM, LA, MARION S, PANICEK D, MOTZER R: Effect of response criteria on outcome assessment for patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol (2003) 22:385.
   Google Scholar
• MOTZER RJ BIR, MICHAELSON MD, REDMAN RG et al.: The 5U11248 Study Group: Phase II trials of SU11248 show antitumour activity in second-line therapy for patients with renal cell carcinoma (RCC) 2005 ASCO Annual Meeting, Orlando, USA (2005):FL2005.
   Google Scholar
• RINI BOR, BUKOWSKI R, MD et al: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, renal cell cancer (RCC). 2005 ASCO Annual Meeting, Orlando, USA (2005).
   Google Scholar
• ESCUDIER BCS, EISEN T, STADLERWM, SCHWARTZ B, M, BUKOWSKI RM: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY-43-9006) in patients with advanced renal cell carcinoma (RCC). 2005 ASCO Annual Meeting, Orlando, USA (2005).
   Google Scholar
• OKA H CY, HOSHINO R, OGAWA 0 et al.: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. (1995) 55(18):4182–4187.
   Google Scholar
• CHONG HVH, GUAN KL: Mechanisms of regulating the Raf kinase family. Cell Signal. (2003) 15(5):463–469.
   PubMed Web of Science ®Google Scholar
• ••Excellent review.
   Google Scholar
• HAY SN: Upstream and downstream of mTOR. Genes Dev. (2004) 18(16):1926–1945.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, STADLER WM, TF et al: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin. Oncol (2004) 22(5):909–918.
   PubMed Web of Science ®Google Scholar
• HIDALGO M: New target, new drug, old paradigm. J. Clin. Oncol (2004) 22(12):2270–2272.
   PubMed Web of Science ®Google Scholar
• HUANG SBM, HOUGHTON PJ: Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. (2003) 2(3):222–232.
   PubMed Web of Science ®Google Scholar
• SHAW VARB, PARK JW, SMALL EJ: A Phase 2 study of UCN-01 in advanced renal cell carcinoma. Proc. Am. Soc. Oncol (2003) 22:442.
   Google Scholar
• DAVIS NB, ANSARI RH, RYAN CW, VOKES EE, VOGELZANG NJ, STADLER WM: A Phase II trial of PS-341 patients (pts) with renal cell cancer (RCC). Proc. Am. Soc. OM Oncol (2003) 22:386.
   Google Scholar
• DRUCKER BJ, BACIK J, M, MARION S, MOTZER RJ: Phase II trial of PS-341 shows response in patients with advanced renal cell carcinoma. Proc. Am. Soc. (2003) 22:386.
   Google Scholar
• COBB PW, VENNER P, VOEGELE J, MOSCOVICI M, MARKOVITZ E, COPPIETERS S: An uncontrolled Phase II multi-center trial evaluating anti-tumor efficacy and safety of BAY-59-8862 in patients with advanced renal cell cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:408.
   Google Scholar
• THOMPSON JA, ESCUDIER B, DUTCHER JP et al: Phase II trial evaluating the safety and efficacy of EP0906 in patients with advanced renal cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:405.
   Google Scholar
• ZHUANG SH, KOTZ H, AGRAWAL M et al: A Phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. Journal of Clinical Oncology ASCO Annual Meeting Proceedings, New Orleans, USA (2004).
   Google Scholar
• MacKLER NJ MB, REDMAN B, RHODES D, CHINNAIYAN A: PI3K/AKT pathway in renal (clear cell) carcinoma via meta-analysis of expression microarrays. 2005 ASCO Annual Meeting, Orlando, USA (2005).
   Google Scholar